Found: 3
Select item for more details and to access through your institution.
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease.
- Published in:
- Cancer (0008543X), 2009, v. 115, n. 17, p. 3924, doi. 10.1002/cncr.24468
- By:
- Publication type:
- Article